Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Dynavax soared by 38.19 percent on Wednesday to close at $15.38 apiece as investors took heart from news that it was set to ...

French pharmaceutical giant Sanofi has announced plans to acquire U.S.-based biotech company Dynavax Technologies in a deal ...

The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.

NEW YORK (AP) — Wall Street was largely unchanged early Wednesday as markets hovered near record levels on a ...

Major stock indexes ended higher Wednesday in a shortened session ahead of a Christmas closure, with the Dow Jones Industrial ...

Sanofi will pay $2.2 billion for Dynavax Techologies as it looks to add another Hepatitis B and new shingles vaccines to its portfolio.

Under the terms of the deal, Sanofi will begin a tender offer to purchase Dynavax's stock for $15.50 per share in cash. That values the biotech at roughly $2.2 billion, a premium of 39% compared to ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Sanofi acquires Dynavax for $2.2B, gaining Heplisav-B and promising vaccine pipeline. Click here to read my analysis of SNY stock and the DVAX acquisition.

Shares of Dynavax Technologies surged after Sanofi said it was buying the vaccine specialist for $2.2 billion in cash. The stock jumped 39% to $15.44 midday Wednesday after hitting a 52-week high of ...

Wall Street was largely unchanged early Wednesday as markets hovered near record levels before the opening bell on a ...